Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Kane Biotech Inc. stock logo
KNE
Kane Biotech
C$0.13
+4.0%
C$0.11
C$0.05
C$0.17
C$17.14M0.56150,909 shs12,000 shs
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
$19.10
+0.1%
$19.10
$18.63
$27.54
$1.91MN/A1,912 shs19,400 shs
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
$5.75
$5.28
$2.08
$12.80
$7.04M-1.6874 shsN/A
Valaris Limited stock logo
VAL
Valaris
$67.76
+0.4%
$69.58
$54.13
$78.92
$4.89B1.13700,407 shs555,127 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Kane Biotech Inc. stock logo
KNE
Kane Biotech
+4.00%0.00%+23.81%+62.50%+18.18%
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
0.00%0.00%0.00%0.00%0.00%
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
0.00%+4.55%+15.00%+5,120.15%+4,366.02%
Valaris Limited stock logo
VAL
Valaris
+0.41%+1.04%-5.86%-1.41%+15.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Kane Biotech Inc. stock logo
KNE
Kane Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/AN/AN/AN/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
3.5584 of 5 stars
3.51.00.00.03.31.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Kane Biotech Inc. stock logo
KNE
Kane Biotech
N/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
0.00
N/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
3.00
Buy$100.0047.58% Upside

Current Analyst Ratings

Latest HEMO, KNE, QPT, SIGY, and VAL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/5/2024
Valaris Limited stock logo
VAL
Valaris
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$105.00 ➝ $102.00
2/23/2024
Valaris Limited stock logo
VAL
Valaris
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$107.00 ➝ $105.00
2/14/2024
Valaris Limited stock logo
VAL
Valaris
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$106.00 ➝ $105.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Kane Biotech Inc. stock logo
KNE
Kane Biotech
C$2.74M6.26C$0.02 per share8.50C($0.07) per share-1.86
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/AN/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/A($2.80) per shareN/A
Valaris Limited stock logo
VAL
Valaris
$1.78B2.75$2.54 per share26.72$27.40 per share2.47

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Kane Biotech Inc. stock logo
KNE
Kane Biotech
-C$4.32M-C$0.03N/AN/A-157.48%N/A-32.70%5/23/2024 (Estimated)
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/A0.00N/AN/AN/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
-$4.15M-$3.60N/AN/AN/AN/A-958.06%N/A
Valaris Limited stock logo
VAL
Valaris
$865.40M$11.695.806.53N/A48.50%5.71%2.40%5/2/2024 (Confirmed)

Latest HEMO, KNE, QPT, SIGY, and VAL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Valaris Limited stock logo
VAL
Valaris
$0.40N/A-$0.40N/AN/AN/A  
3/26/2024Q4 2023
Kane Biotech Inc. stock logo
KNE
Kane Biotech
N/A-C$0.01-C$0.01-C$0.01N/AC$0.04 million
2/21/2024Q4 2023
Valaris Limited stock logo
VAL
Valaris
$0.29$0.61+$0.32-$10.08$484.00 million$483.80 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Kane Biotech Inc. stock logo
KNE
Kane Biotech
N/AN/AN/AN/AN/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
$0.080.42%N/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/AN/AN/AN/AN/A
Valaris Limited stock logo
VAL
Valaris
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Kane Biotech Inc. stock logo
KNE
Kane Biotech
1,164.24
0.37
0.39
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/AN/AN/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
N/A
0.03
0.02
Valaris Limited stock logo
VAL
Valaris
0.54
1.71
1.71

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Kane Biotech Inc. stock logo
KNE
Kane Biotech
N/A
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/A
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
10.01%
Valaris Limited stock logo
VAL
Valaris
96.74%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Kane Biotech Inc. stock logo
KNE
Kane Biotech
N/A131.84 millionN/ANot Optionable
AdvisorShares Q Portfolio Blended Allocation ETF stock logo
QPT
AdvisorShares Q Portfolio Blended Allocation ETF
N/A100,000N/ANot Optionable
Sigyn Therapeutics, Inc. stock logo
SIGY
Sigyn Therapeutics
51.22 million264,000Not Optionable
Valaris Limited stock logo
VAL
Valaris
5,98572.41 million72.33 millionOptionable

HEMO, KNE, QPT, SIGY, and VAL Headlines

SourceHeadline
Valaris Limited (NYSE:VAL) Given Consensus Recommendation of "Buy" by AnalystsValaris Limited (NYSE:VAL) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - April 26 at 3:08 AM
Valaris (NYSE:VAL) Upgraded by StockNews.com to "Sell"Valaris (NYSE:VAL) Upgraded by StockNews.com to "Sell"
americanbankingnews.com - April 26 at 2:18 AM
Equinor rolls up its sleeves for imminent Argentina exploration wellEquinor rolls up its sleeves for imminent Argentina exploration well
upstreamonline.com - April 25 at 9:14 AM
Valaris (VAL) Set to Announce Quarterly Earnings on ThursdayValaris (VAL) Set to Announce Quarterly Earnings on Thursday
americanbankingnews.com - April 25 at 2:32 AM
Louisiana State Employees Retirement System Takes $1.21 Million Position in Valaris Limited (NYSE:VAL)Louisiana State Employees Retirement System Takes $1.21 Million Position in Valaris Limited (NYSE:VAL)
marketbeat.com - April 23 at 4:51 AM
John Fredriksen ally wins seat on board of potential takeover target International SeawaysJohn Fredriksen ally wins seat on board of potential takeover target International Seaways
tradewindsnews.com - April 18 at 10:48 PM
Valaris Limited (NYSE:VAL) Shares Sold by River Road Asset Management LLCValaris Limited (NYSE:VAL) Shares Sold by River Road Asset Management LLC
marketbeat.com - April 18 at 9:34 AM
Interocean announces UT technology demonstrationInterocean announces UT technology demonstration
zawya.com - April 16 at 8:33 AM
Mutual of America Capital Management LLC Acquires 38,367 Shares of Valaris Limited (NYSE:VAL)Mutual of America Capital Management LLC Acquires 38,367 Shares of Valaris Limited (NYSE:VAL)
marketbeat.com - April 14 at 6:11 AM
Valaris Schedules First Quarter 2024 Earnings Release and Conference CallValaris Schedules First Quarter 2024 Earnings Release and Conference Call
businesswire.com - April 11 at 4:30 PM
Aramco Suspends Valaris Rig ContractAramco Suspends Valaris Rig Contract
rigzone.com - April 11 at 1:38 AM
Valaris (VAL) Receives Rigs Suspension Notice From AramcoValaris (VAL) Receives Rig's Suspension Notice From Aramco
zacks.com - April 9 at 2:26 PM
Lancaster Investment Management Buys Shares of 400,116 Valaris Limited (NYSE:VAL)Lancaster Investment Management Buys Shares of 400,116 Valaris Limited (NYSE:VAL)
marketbeat.com - April 9 at 12:12 PM
Port Everglades marks commissioning of new container cranesPort Everglades marks commissioning of new container cranes
en.portnews.ru - April 7 at 11:30 AM
Valaris faces rig suspension in Saudi joint ventureValaris faces rig suspension in Saudi joint venture
investing.com - April 6 at 2:41 AM
Aramco Suspends Another Jack-Up RigAramco Suspends Another Jack-Up Rig
oedigital.com - April 5 at 4:40 PM
Suspension notice for Valaris joint ventureSuspension notice for Valaris joint venture
royalgazette.com - April 5 at 4:40 PM
Saudi Aramco suspends offshore rig deal with New York-listed playerSaudi Aramco suspends offshore rig deal with New York-listed player
upstreamonline.com - April 5 at 1:44 AM
Aramco suspends jackup contract with offshore drillerAramco suspends jackup contract with offshore driller
upstreamonline.com - April 4 at 8:43 PM
Valaris (NYSE:VAL) Shares Gap Down to $76.66Valaris (NYSE:VAL) Shares Gap Down to $76.66
marketbeat.com - April 4 at 2:02 PM
Valaris Limited (NYSE:VAL) Shares Purchased by Vanguard Group Inc.Valaris Limited (NYSE:VAL) Shares Purchased by Vanguard Group Inc.
marketbeat.com - April 3 at 4:09 AM
Valaris: Buy Despite Near-Term Jackup Market HeadwindsValaris: Buy Despite Near-Term Jackup Market Headwinds
seekingalpha.com - April 2 at 7:31 PM
VAL Quantitative Stock AnalysisVAL Quantitative Stock Analysis
nasdaq.com - April 1 at 6:26 PM
Valaris Limited (NYSE:VAL) Receives Consensus Recommendation of "Buy" from AnalystsValaris Limited (NYSE:VAL) Receives Consensus Recommendation of "Buy" from Analysts
marketbeat.com - April 1 at 4:14 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Kane Biotech logo

Kane Biotech

CVE:KNE
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops pet oral care products under the StrixNB and bluestem brands; and animal and human wound care solutions under the DispersinB name. It also offers scalp care products under the DermaKB brand name; and wound care products under the Coactiv+ brand name, as well as other products under the goldstem, silkstem, Aledex, and DermaKB Biofilm brand names. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada.
AdvisorShares Q Portfolio Blended Allocation ETF logo

AdvisorShares Q Portfolio Blended Allocation ETF

NYSEARCA:QPT
Sigyn Therapeutics logo

Sigyn Therapeutics

OTCMKTS:SIGY
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.
Valaris logo

Valaris

NYSE:VAL
Valaris Limited, together with its subsidiaries, provides offshore contract drilling services Gulf of Mexico, South America, North Sea, the Middle East, Africa, and the Asia Pacific. The company operates through four segments: Floaters, Jackups, ARO, and Other. It owns an offshore drilling rig fleet, which include drillships, dynamically positioned semisubmersible rigs, moored semisubmersible rig, and jackup rigs. It serves international, government-owned, and independent oil and gas. Valaris Limited was founded in 1975 and is based in Hamilton, Bermuda.